Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼ö¼úÀü È­Çпä¹ýÀ» ½ÃÇàÇÑ ½Äµµ¾ÏÁ¾ÀÇ º´¸®ÇÐÀû º¯È­¿Í P-glycoprotein ¹ßÇö¾ç»ó Pathologic Observations and P-glycoprotein Expresssion in Esophageal Carcinomas Treated with Preoperative chemotherapy

´ëÇѾÏÇÐȸÁö 1994³â 26±Ç 4È£ p.529 ~ 533
¼Ò¼Ó »ó¼¼Á¤º¸
ÇÏâ¿ø Á¶°æÀÚ/½É¿µ¸ñ/Á¶ÀçÀÏ/ÀåÀÚÁØ

Abstract


Neoadjuvant chemotherapy of esophageal cancers is recently considered to be beneficial to downstaging of tumors. This study was aimed to describe morphologic alterations and expression of P-glycoprotein in esophageal cancers after chemotherapy
and
discuss their clinical significances. Eleven cases of esophageal cancers which were surgically resected 1-5 cycles of chemotherapy with C-DDP/VP-16/5-FU(PEF) or C-DDP/5-FU(FP) were reviewed On microscopic examination, all of 11 cases(100%)
revealed
no
major pathologic alteration. Only five cases945%) showed non-specific partial pathologic responses, histologically observing foreign body reaction, calcification, necrosis, desmoplasia, vascular dilatation, and nuclear anaplasia. The changes were
also
observed in metastatic tumors in regional lymph nodes. The presence of non-specific pathologic responses and downstaging of tumors did not correlate each other. Immunohistochemically, all of the cases were negative for P-glycoprotein. Our data
suggest
that PEF or FP neoadjuvant chemotherapy for esophageal cancers is ineffecitive.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS